Table 2.
Characteristics of the included studies.
| Study Name (Year of Publication) |
Treatment Arms | N | Age—yrs. Median (range) |
Female Sex No. (%) |
ECOG PS No. (%) | Histologic Type No. (%) | PD-L1 Status |
|---|---|---|---|---|---|---|---|
| KEYNOTE-189 (2018) | Pembrolizumab 200 mg/body e3w plus platinum-based chemotherapy |
410 | 65 (34–84) | 156 (38.0) | PS0: 186 (45.4) PS1: 221 (53.9) PS2: 1 (0.2) Missing: 2 (0.5) |
Adenocarcinoma 394 (96.1) | ≥1% 260 (63.4) |
| Other 16 (3.9) | ≥50% 132 (32.2) | ||||||
| Platinum-based chemotherapy | 206 | 63.5 (34–84) | 97 (47.1) | PS0: 80 (38.8) | Adenocarcinoma 198 (96.1) | ≥1% 128 (62.1) | |
| PS1: 125 (60.7) | Other 8 (3.6) | ≥50% 70 (34.0) | |||||
| Missing: 1 (0.5) | |||||||
| Total, 616 | |||||||
| KEYNOTE-407 (2018) | Pembrolizumab 200 mg/body e3w plus platinum-based chemotherapy |
278 | 65 (29–87) | 58 (20.9) | PS0: 73 (26.3) | Squamous: 272 (97.8) | ≥1% 176 (63.3) |
| PS1: 205 (73.7) | Adenosquamous: 6 (2.2) | ≥50% 73 (26.3) | |||||
| Platinum-based chemotherapy | 281 | 65 (36–88) | 46 (16.4) | PS0: 90 (32.0) | Squamous: 274 (97.5) | ≥1% 177 (63.0) | |
| PS1: 191 (68.0) | Adenosquamous: 7 (2.5) | ≥50% 73 (26.0) | |||||
| Total, 559 | |||||||
| Pembrolizumab 200 mg/body e3w | 637 | 63.0 (57.0–69.0) | 187 (29%) | PS0: 198 (31) | Squamous: 243 (38) | ≥1% 637 (100) | |
| PS1: 439 (69) | Non-squamous: 394 (62) | ≥50% 299 (46.9) | |||||
| Platinum-based chemotherapy | 637 | 63.0 (57.0–69.0) | 185 (29%) | PS0: 192 (30) | Squamous: 249 (39) | ≥1% 637 (100.0) | |
| PS1: 445(70) | Non-squamous: 388(61) | ≥50% 300 (47.1) | |||||
| Total, 1274 | |||||||
| CheckMate 227 (2019) | Nivolumab 3 mg/kg e2w plus ipilimumab 1 mg/kg e6w |
583 | 64 (26–87) | 190 (32.6) | PS0: 204 (35.0) | Squamous: 163 (28.0) | ≥1% 396 (67.9) |
| PS1: 377 (64.7) | Non-squamous: 419 (71.9) | ≥50% 205 (35.2) | |||||
| Other or missing: 2 (0.3) | Missing data: 1 (0.2) | ||||||
| Nivolumab 240 mg/body e2w | 396 | 64 (27–85) | 124 (31.3) | PS0: 142 (35.9) | Squamous: 117 (29.5) | ≥1% 396 (100.0) | |
| PS1: 252 (63.6) | Non-squamous: 279 (70.5) | ≥50% 214 (54.0) | |||||
| Other or missing: 2 (0.5) | Missing data: 0 (0) | ||||||
| Platinum based chemotherapy | 583 | 64 (29–87) | 198 (34.0) | PS0: 191 (32.8) | Squamous: 162 (27.8) | ≥1% 397 (68.1) | |
| PS1: 386 (66.2) | Non-squamous: 421 (72.2) | ≥50% 192 (32.9) | |||||
| Other or missing: 6 (1.0) | Missing data: 0 (0) | ||||||
| Total, 1562 |
The intention-to-treat (ITT) population contains all participants who were randomized, irrespective of whether an intervention was performed. N, number of patients; yrs., years; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD-L1, programmed cell death ligand 1; e3w, every three weeks; e2w, every two weeks, e6w, every 6 weeks.